Edoxaban, a Novel Oral Factor Xa Inhibitor (Q38412381)

2 September 2017

1 reference

title

Edoxaban, a Novel Oral Factor Xa Inhibitor (English)

1 reference

2 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Anastasia L Armbruster

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Chelsea Minor

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

8 April 2015

1 reference

Annals of Pharmacotherapy

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

843-850

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Edoxaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015579426

21 January 2018

Identifiers

DOI

10.1177/1060028015579426

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855704%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference